ArticleFrontiers in oncology2023

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer.

Layal Al Mahmasani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.